The U.S. Food and Drug Administration (FDA) has approved Fiasp (insulin aspart injection; Novo Nordisk), a rapid-acting human insulin analog, for use in children with diabetes. Fiasp has an additional ingredient, niacinamide, which increases absorption speed, and was previously approved for use in adults and in insulin pumps. Read more